Analystreport

Acorda Therapeutics, Inc. (NASDAQ: ACOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.

Acorda Therapeutics, Inc.  (ACOR) 
Last acorda therapeutics, inc. earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: acorda.com/investors